aod9604 fda approved AOD 9604 5MG AOD-9604 5mg | Metabolic Research

W.et al (2017)

Key Findings from Preclinical Research Insights from Animal Studies While we always look to human trials for definitive answers, preclinical research offers a powerful window into how a compound works

Reconstituted solution at 2-8C, use within 30 days

50mg Per Capsule Oral Administration NNMT Target Enzyme 22+ BHRC Locations Available Option An oral NNMT inhibitor designed to support cellular energy metabolism and metabolic function through targeted enzyme modulation

AOD-9604 vs GLP-2 T GLP-2 T (tirzepatide) extends the GLP-1 S mechanism further by co-activating GIP receptors alongside GLP-1, producing a broader incretin effect and generally stronger weight-loss outcomes in published research than single-pathway GLP-1 agonists

Injection is given once a week if levels are low and once a month for maintenance